Cargando…

Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH

Empagliflozin, an established treatment for type 2 diabetes (T2DM), has shown beneficial effects on liver steatosis and fibrosis in animals and in humans with T2DM, non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH). However, little is known about the effects of empagliflozin on li...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perakakis, Nikolaos, Chrysafi, Pavlina, Feigh, Michael, Veidal, Sanne Skovgard, Mantzoros, Christos S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232001/ https://www.ncbi.nlm.nih.gov/pubmed/34199317 http://dx.doi.org/10.3390/ijms22126332

Ejemplares similares

Both Elafibranor and Liraglutide Improve NAFLD / NASH but Affect Differentially the Hepatic Lipidome and Metabolome in a Diet-Induced Obese and Biopsy-Confirmed Mouse Model of NASH
por: Perakakis, Nikolaos, et al.
Publicado: (2021)

The Selective Peroxisome Proliferator‐Activated Receptor Gamma Modulator CHS‐131 Improves Liver Histopathology and Metabolism in a Mouse Model of Obesity and Nonalcoholic Steatohepatitis
por: Perakakis, Nikolaos, et al.
Publicado: (2020)

Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH
por: Baandrup Kristiansen, Maria Nicoline, et al.
Publicado: (2019)

Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet‐induced obese and biopsy‐confirmed mouse model of NASH
por: Møllerhøj, Mathias B., et al.
Publicado: (2022)

Leptin alters energy intake and fat mass but not energy expenditure in lean subjects
por: Chrysafi, Pavlina, et al.
Publicado: (2020)

Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis
por: Tølbøl, Kirstine S, et al.
Publicado: (2018)

Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH
por: Roth, Jonathan D., et al.
Publicado: (2019)

The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease
por: Perakakis, Nikolaos, et al.
Publicado: (2020)

OR01-5 Leptin Acts through Altering Energy Intake and Lipolysis to Reduce Body Weight but Has No Effect on Energy Expenditure, Physical Activity, and Sympathetic Nervous System in Humans
por: Chrysafi, Pavlina, et al.
Publicado: (2019)

Association of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease
por: Boutari, Chrysoula, et al.
Publicado: (2018)

PCSK9 inhibition and cholesterol homeostasis in insulin producing β-cells
por: Päth, Günter, et al.
Publicado: (2022)

INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis
por: Roth, Jonathan D, et al.
Publicado: (2018)

Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis.
por: Boland, Michelle L., et al.
Publicado: (2020)

Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial
por: Peradze, Natia, et al.
Publicado: (2019)

Phosphodiesterase inhibition mediates matrix metalloproteinase activity and the level of collagen degradation fragments in a liver fibrosis ex vivo rat model
por: Veidal, Sanne Skovgård, et al.
Publicado: (2012)

Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH
por: Hupa-Breier, Katharina Luise, et al.
Publicado: (2021)

Serum Markers of Liver Fibrosis: Combining the BIPED Classification and the Neo-Epitope Approach in the Development of New Biomarkers
por: Veidal, Sanne Skovgård, et al.
Publicado: (2010)

Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source
por: Boland, Michelle L, et al.
Publicado: (2019)

Regulation of mouse hepatic genes in response to diet induced obesity, insulin resistance and fasting induced weight reduction
por: Raab, R Michael, et al.
Publicado: (2005)

Multi-omics characterization of a diet-induced obese model of non-alcoholic steatohepatitis
por: Ægidius, Helene M., et al.
Publicado: (2020)

Procollagen type I N-terminal propeptide (PINP) is a marker for fibrogenesis in bile duct ligation-induced fibrosis in rats
por: Veidal, Sanne Skovgård, et al.
Publicado: (2010)

Quantifying Fibrinogen-Dependent Aggregation of Red Blood Cells in Type 2 Diabetes Mellitus
por: Deng, Yixiang, et al.
Publicado: (2020)

MAFLD/NAFLD Biopsy-Free Scoring Systems for Hepatic Steatosis, NASH, and Fibrosis Diagnosis
por: Segura-Azuara, Nancy de los Ángeles, et al.
Publicado: (2022)

An optimized protocol for isolation of hepatic leukocytes retrieved from murine and NASH liver biopsies
por: Bahrami, Ehsan, et al.
Publicado: (2023)

Biopsy proven acute interstitial nephritis after treatment with moxifloxacin
por: Chatzikyrkou, Christos, et al.
Publicado: (2010)

Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis
por: Hansen, Henrik H., et al.
Publicado: (2020)

Prognostic Value of the Alcoholic Hepatitis Histologic Score in Korean Patients with Biopsy-Proven Alcoholic Hepatitis
por: Lee, Dong Hyeon, et al.
Publicado: (2020)

Confocal Microscopy in Biopsy Proven Argyrosis
por: Palamar, Melis, et al.
Publicado: (2013)

Negative Biopsy after Referral for Biopsy-Proven Gastric Cancer
por: Tae, Chung Hyun, et al.
Publicado: (2016)

Clinicobiochemical prediction of biopsy-proven cases of severe hepatic fibrosis in patients with chronic hepatitis C infection
por: Jin, Young-Joo, et al.
Publicado: (2014)

The spectrum of biopsy-proven renal diseases in Korea
por: Lim, Beom Jin
Publicado: (2020)

Malignant Degeneration of Biopsy-Proven Hamartoma to Chondrosarcoma
por: Schenkel, Rachel, et al.
Publicado: (2020)

Electroanatomical features of biopsy-proven cardiac amyloidosis
por: Casella, M, et al.
Publicado: (2023)

Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative
por: Stokman, Geurt, et al.
Publicado: (2020)

Hepatic Expression Patterns of Inflammatory and Immune Response Genes Associated with Obesity and NASH in Morbidly Obese Patients
por: Bertola, Adeline, et al.
Publicado: (2010)

Empagliflozin protects mice against diet-induced obesity, insulin resistance and hepatic steatosis
por: Radlinger, Bernhard, et al.
Publicado: (2022)

Obesity is not associated with progression to end stage renal disease in patients with biopsy-proven glomerular diseases
por: Elyan, Benjamin M. P., et al.
Publicado: (2019)

Immunosuppression status of liver transplant recipients with hepatitis C affects biopsy-proven acute rejection
por: Kim, Jong Man, et al.
Publicado: (2016)

Renal outcome in biopsy proven cases of graft pyelonephritis
por: Varma, P. P., et al.
Publicado: (2014)

Ocular Manifestations of Biopsy-Proven Pulmonary Sarcoidosis in Korea
por: Choi, Seung Yong, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_o565j24lle331184poqgmo8oii